

February 1, 2022

CefTRIAxone SmartPak®, Midazolam, Milrinone, Vasopressin Allocation Notice

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that due to production delays, we will be placing our **CefTRIAxone for Injection, 100g SmartPak®, Midazolam Injection, 1mg/mL MD Vial 10mL** and, **Milrinone Lactate Injection 1mg/mL SD Vial 20mL** on allocation. Contract customers will be allocated **100% of their historical average monthly volumes** effective today, **February 1, 2022**.

We are pleased to advise that allocations for our **Vasopressin Injection 20 units/mL MD Vial 1mL** will be increased from 150% to **200% of historical monthly average demand**. These changes will be effective today, **February 1, 2022**.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Allocation Start Date
02409968	CP1456B1	967774	64206	CefTRIAxone for Injection, 100g SmartPak®	100% Allocation Feb. 1, 2022
02242904	C410110	922559	23016	Midazolam Injection, 1mg/mL MD Vial 10mL	100% Allocation Feb. 1, 2022
02244622	C601720	922602	2915	Milrinone Lactate Injection 1mg/mL SD Vial 20mL	100% Allocation Feb. 1, 2022
02139502	C30201	922924	594333	Vasopressin Injection 20 units/mL MD Vial 1mL	200% Allocation (previously 150%) Feb. 1, 2022

We recognize the difficulties and inconvenience that you may encounter as a result of this allocation, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact Customer Service at (877) 821-7724.

Sincerely,



George Shamsoun
 Associate Director – Marketing, IV Drugs
george.shamsoun@fresenius-kabi.com